tiprankstipranks
Trending News
More News >
Telesis Bio, Inc. (TBIO)
:TBIO
US Market
Advertisement

Telesis Bio (TBIO) Price & Analysis

Compare
138 Followers

TBIO Stock Chart & Stats


Telesis Bio News

TBIO FAQ

What was Telesis Bio, Inc.’s price range in the past 12 months?
Telesis Bio, Inc. lowest stock price was $0.01 and its highest was $5.17 in the past 12 months.
    What is Telesis Bio, Inc.’s market cap?
    Telesis Bio, Inc.’s market cap is $940.72K.
      When is Telesis Bio, Inc.’s upcoming earnings report date?
      Telesis Bio, Inc.’s upcoming earnings report date is Aug 12, 2025 which is 23 days ago.
        How were Telesis Bio, Inc.’s earnings last quarter?
        Currently, no data Available
        Is Telesis Bio, Inc. overvalued?
        According to Wall Street analysts Telesis Bio, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Telesis Bio, Inc. pay dividends?
          Telesis Bio, Inc. does not currently pay dividends.
          What is Telesis Bio, Inc.’s EPS estimate?
          Telesis Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Telesis Bio, Inc. have?
          Telesis Bio, Inc. has 78,393,530 shares outstanding.
            What happened to Telesis Bio, Inc.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Telesis Bio, Inc.?
            Among the largest hedge funds holding Telesis Bio, Inc.’s share is Woodline Partners LP. It holds Telesis Bio, Inc.’s shares valued at 0.

              Company Description

              Telesis Bio, Inc.

              Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

              Telesis Bio (TBIO) Earnings & Revenues

              Similar Stocks
              Company
              Price & Change
              Follow
              PAVmed
              Bone Biologics
              INVO Fertility
              Vivos Therapeutics
              Tivic Health Systems

              Ownership Overview

              0.05%0.06%99.94%
              0.06% Other Institutional Investors
              99.94% Public Companies and
              Individual Investors

              Options Prices

              Currently, No data available
              ---
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis